Led by B2H, the CHU de Liège and the ULg have launched their collaboration with Janssen Pharmaceutica

Led by B2H, the CHU de Liège and the ULg have launched their collaboration with Janssen Pharmaceutica

The University of Liège (ULg), the Centre Hospitalier Universitaire (CHU) de Liège, Janssen Pharmaceutica and Janssen-Cilag have signed on February 2nd a charter to launch their collaboration, aiming at strengthening their mutual competences in the setting-up and execution of multidisciplinary research projects and thus, accelerating patient access to medical innovations.

The objective is to promote the operational networking of academic, hospital and industrial expertise in five medical innovation domains:

  1. Acceleration and optimization of clinical research through access to a pan-European project facilitating the exchange of data between research centers
  2. Intensification of Phase I research of new drugs for cancer, type II diabetes, Alzheimer’s disease, rheumatoid arthritis and psoriasis
  3. Interdisciplinary collaboration and exchange of technological and scientific knowledge in drug development and production
  4. Collaboration for improved patient outcome by (1) developing the innovative concept of home hospitalization as a form of oncological patient care and (2) improving the healthcare pathway of cancerous patients
  5. Access to the JLINX investment and incubator model on the Janssen campus in Beerse

Picture © Michel Houet: from left to right, Tom Aelbrecht (Janssen Pharmaceutica), Pr. Rudi Cloots (ULg), Sonja Willems (Janssen Benelux), Julien Compère (CHU de Liège).

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials